OUR BUSINESS

CONCEPT & PIPELINE

SAVES LIVES AND HEALTH CARE COSTS

U.S. Preventive Services Task Force recommends screening starting at age 45, and testing every 3 years (for average risk individuals) when using a combined stool DNA/fecal immunochemical test. 10

Making CRC prevention a standard test every 3 years after age 45 is advised to detect early-stage anomalies.10

Regular CRC testing means fewer unnecessary colonoscopies and higher user acceptance, directly leading to increased screening participation. 10

Annual testing costs per patient are minimal (especially when compared to late-stage treatments of CRC).

  • Enormous savings in first level treatment costs  (one case of metastasized CRC represents substantial treatment costs).

  • Reduced second level treatment costs.

Commercial Pipeline Development: Future Products

In addition to our flagship ColoAlert product, Mainz Biomed is also developing:

Developing a novel early detection pancreatic cancer screening test

* Artist rendering. Product under development.

GenoStick Technology

If you would like to be kept up to date with the very latest news, please enter your details in the form and we will keep you updated.